Dora Ho

Publications

• Clinical significance of low cytomegalovirus DNA levels in human plasma. Waggoner J, Ho DY, Libiran P, Pinsky BA. J Clin Microbiol. 2012; 50 (7): 2378-83
• Brain abscess caused by Phaeoacremonium parasiticum in an immunocompromised patient. McNeil CJ, Luo RF, Vogel H, Banaei N, Ho DY. J Clin Microbiol. 2011; 49 (3): 1171-4
• Early CMV viremia is associated with impaired viral control following nonmyeloablative hematopoietic cell transplantation with a total lymphoid irradiation and antithymocyte globulin preparative regimen. Schaenman JM, Shashidhar S, Rhee C, Wong J, Navato S, Wong RM, Ho DY, Arai S, Johnston L, Brown JM. Biol Blood Marrow Transplant. 2011; 17 (5): 693-702
• Treatment of acyclovir-resistant herpes simplex virus with continuous infusion of high-dose acyclovir in hematopoietic cell transplant patients. Kim JH, Schaenman JM, Ho DY, Brown JM. Biol Blood Marrow Transplant. 2011; 17 (2): 259-64
• Yield of diagnostic procedures for invasive fungal infections in neutropenic febrile patients with chest computed tomography abnormalities. Ho DY, Lin M, Schaenman J, Rosso F, Leung AN, Coutre SE, Sista RR, Montoya JG. Mycoses. 2011; 54 (1): 59-70
• Varicella Zoster Virus Ho DY, Arvin Am, Newland JG. In: Yu VL, Weber R, Raoult D (eds.), Antinicrobial Therapy and Vaccines 3rd edition. 2009
• Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Talbot HK, Keitel W, Cate TR, Treanor J, Campbell J, Brady RC, Graham I, Dekker CL, Ho D, Winokur P, Walter E, Bennet J, Formica N, Hartel G, Skeljo M, Edwards KM. Vaccine. 2008; 26 (32): 4057-61
• Varicella Zoster Virus Infections Ho DY, Arvin AM. In: Blume KG, Negrin RS, Foramn SJ, Appelbaum (eds.), Thomas’ Hematopoietic Cell Transplantation 4th edition.. 2008 Chapter 92
• Treating disseminated fusariosis: amphotericin B, voriconazole or both? Ho DY, Lee JD, Rosso F, Montoya JG. Mycoses. 2007; 50 (3): 227-31
• Anaphylactoid reaction to ciprofloxacin. Ho DY, Song JC, Wang CC. Ann Pharmacother. 2003 Jul-Aug; 37 (7-8): 1018-23
• Potassium channel gene therapy can prevent neuron death resulting from necrotic and apoptotic insults. Lee AL, Dumas TC, Tarapore PE, Webster BR, Ho DY, Kaufer D, Sapolsky RM. J Neurochem. 2003; 86 (5): 1079-88
• Calbindin d28k overexpression protects striatal neurons from transient focal cerebral ischemia. Yenari MA, Minami M, Sun GH, Meier TJ, Kunis DM, McLaughlin JR, Ho DY, Sapolsky RM, Steinberg GK. Stroke. 2001; 32 (4): 1028-35
• Interactions among ascorbate, dehydroascorbate and glucose transport in cultured hippocampal neurons and glia. Patel M, McIntosh L, Bliss T, Ho D, Sapolsky R. Brain Res. 2001; 916 (1-2): 127-35
• Neuroprotective effects of an adenoviral vector expressing the glucose transporter: a detailed description of the mediating cellular events. Gupta A, Ho DY, Brooke S, Franklin L, Roy M, McLaughlin J, Fink SL, Sapolsky RM. Brain Res. 2001; 908 (1): 49-57
• An adenoviral vector expressing the glucose transporter protects cultured striatal neurons from 3-nitropropionic acid. Fink SL, Ho DY, McLaughlin J, Sapolsky RM. Brain Res. 2000; 859 (1): 21-5
• Gene therapies that enhance hippocampal neuron survival after an excitotoxic insult are not equivalent in their ability to maintain synaptic transmission. Dumas TC, McLaughlin JR, Ho DY, Lawrence MS, Sapolsky RM. Exp Neurol. 2000; 166 (1): 180-9
• Limitations in the neuroprotective potential of gene therapy with Bcl-2. Phillips RG, Lawrence MS, Ho DY, Sapolsky RM. Brain Res. 2000; 859 (2): 202-6
• Neuroprotective potential of a viral vector system induced by a neurological insult. Ozawa CR, Ho JJ, Tsai DJ, Ho DY, Sapolsky RM. Proc Natl Acad Sci U S A. 2000; 97 (16): 9270-5
• Sparing of neuronal function postseizure with gene therapy. McLaughlin J, Roozendaal B, Dumas T, Gupta A, Ajilore O, Hsieh J, Ho D, Lawrence M, McGaugh JL, Sapolsky R. Proc Natl Acad Sci U S A. 2000; 97 (23): 12804-9
• Calbindin D28K gene transfer via herpes simplex virus amplicon vector decreases hippocampal damage in vivo following neurotoxic insults. Phillips RG, Meier TJ, Giuli LC, McLaughlin JR, Ho DY, Sapolsky RM. J Neurochem. 1999; 73 (3): 1200-5
• Delivery of herpes simplex virus amplicon-based vectors to the dentate gyrus does not alter hippocampal synaptic transmission in vivo. Dumas T, McLaughlin J, Ho D, Meier T, Sapolsky R. Gene Ther. 1999; 6 (10): 1679-84
• Gene therapy with HSP72 is neuroprotective in rat models of stroke and epilepsy. Yenari MA, Fink SL, Sun GH, Chang LK, Patel MK, Kunis DM, Onley D, Ho DY, Sapolsky RM, Steinberg GK. Ann Neurol. 1998; 44 (4): 584-91
• Gene transfer of calbindin D28k cDNA via herpes simplex virus amplicon vector decreases cytoplasmic calcium ion response and enhances neuronal survival following glutamatergic challenge but not following cyanide. Meier TJ, Ho DY, Park TS, Sapolsky RM. J Neurochem. 1998; 71 (3): 1013-23
• Gene transfer therapy for cerebral ischemia Yenari MA, Fink SL, Lawrence MS, Sun GH, McLaughlin J, Onley D, Ho DY, Sapolsky RM and Steinberg G. In: Krieglstein J and Oberpichler-Schwenk H (eds.), Pharmacology of Cerebral Ischemia, Medpharm, Stuttgart. 1998: 453-459
• The ins and outs of on and off. Sapolsky RM, Ho DY, McLaughlin J. Nat Biotechnol. 1998; 16 (6): 516
• Defective herpes simplex virus vectors expressing the rat brain stress-inducible heat shock protein 72 protect cultured neurons from severe heat shock. Fink SL, Chang LK, Ho DY, Sapolsky RM. J Neurochem. 1997; 68 (3): 961-9
• Gene therapy for the nervous system. Ho DY, Sapolsky RM. Sci Am. 1997; 276 (6): 116-20
• Herpes simplex viral vectors expressing Bcl-2 are neuroprotective when delivered after a stroke. Lawrence MS, McLaughlin JR, Sun GH, Ho DY, McIntosh L, Kunis DM, Sapolsky RM, Steinberg GK. J Cereb Blood Flow Metab. 1997; 17 (7): 740-4
• Increased expression of calbindin D28k via herpes simplex virus amplicon vector decreases calcium ion mobilization and enhances neuronal survival after hypoglycemic challenge. Meier TJ, Ho DY, Sapolsky RM. J Neurochem. 1997; 69 (3): 1039-47
• A herpes simplex virus vector overexpressing the glucose transporter gene protects the rat dentate gyrus from an antimetabolite toxin. Dash R, Lawrence M, Ho D, Sapolsky R. Exp Neurol. 1996; 137 (1): 43-8
• Energy and glutamate dependency of 3-Nitropropionic acid neurotoxicity in culture. Fink SL, Ho DY, Sapolsky RM. Exp Neurol. 1996; 138 (2): 298-304
• Herpes simplex viral vectors expressing bcl-2 are neuroprotective against focal ischemia Yenari M, Lawrence M, Sun G, Ho DY, Kunis D, Sapolsky R, Steinberg G. In: Krieglstein J (ed.) Pharmacology of Cerebral Ischemia, Medpharm, Stuttgart. 1996: 537-543
• Inducible gene expression from defective herpes simplex virus vectors using the tetracycline-responsive promoter system. Ho DY, McLaughlin JR, Sapolsky RM. Brain Res Mol Brain Res. 1996; 41 (1-2): 200-9
• Overexpression of Bcl-2 with herpes simplex virus vectors protects CNS neurons against neurological insults in vitro and in vivo. Lawrence MS, Ho DY, Sun GH, Steinberg GK, Sapolsky RM. J Neurosci. 1996; 16 (2): 486-96
• Overexpression of the glucose transporter gene with a herpes simplex viral vector protects striatal neurons against stroke. Lawrence MS, Sun GH, Kunis DM, Saydam TC, Dash R, Ho DY, Sapolsky RM, Steinberg GK. J Cereb Blood Flow Metab. 1996; 16 (2): 181-5
• Defective herpes simplex virus vectors expressing the rat brain glucose transporter protect cultured neurons from necrotic insults. Ho DY, Saydam TC, Fink SL, Lawrence MS, Sapolsky RM. J Neurochem. 1995; 65 (2): 842-50
• Herpes simplex virus vector system: analysis of its in vivo and in vitro cytopathic effects. Ho DY, Fink SL, Lawrence MS, Meier TJ, Saydam TC, Dash R, Sapolsky RM. J Neurosci Methods. 1995; 57 (2): 205-15
• Herpes simplex virus vectors overexpressing the glucose transporter gene protect against seizure-induced neuron loss. Lawrence MS, Ho DY, Dash R, Sapolsky RM. Proc Natl Acad Sci U S A. 1995; 92 (16): 7247-51
• Multiple vectors effectively achieve gene transfer in a murine cardiac transplantation model. Immunosuppression with TGF-beta 1 or vIL-10. Qin L, Chavin KD, Ding Y, Favaro JP, Woodward JE, Lin J, Tahara H, Robbins P, Shaked A, Ho DY. Transplantation. 1995; 59 (6): 809-16
• Necrotic neuron death, its exacerbation by stress, and its diminution by gene transfer approaches Sapolsky R, Ho DY. In: Ottoson D, Bartfai T, Hokfelt T, Fuxe K (eds.) Challenges and Perspectives in Neuroscience, Wenner-Gren International Series, Pergamon. 1995: 179-210
• Use of herpes simplex virus vectors for protection from necrotic neuron death Ho DY, Lawrence M, Meier T, Fink S, Dash R, Saydam T, Sapolsky R. In: Kaplitt M, Loewy A (eds.), Viral Vectors, Academic Press. 1995: 133-155
• Amplicon-based herpes simplex virus vectors. Ho DY, Methods Cell Biol. 1994: 43 Pt A 191-210
• Altering central nervous system physiology with a defective herpes simplex virus vector expressing the glucose transporter gene. Ho DY, Mocarski ES, Sapolsky RM. Proc Natl Acad Sci U S A. 1993; 90 (8): 3655-9
• Herpes simplex virus latency: molecular aspects. Ho DY, Prog Med Virol. 1992: 39 76-115
• Neutralizing epitopes on herpes simplex virus-1-expressed rotavirus VP7 are dependent on coexpression of other rotavirus proteins. Dormitzer PR, Ho DY, Mackow ER, Mocarski ES, Greenberg HB. Virology. 1992; 187 (1): 18-32
• Herpes simplex virus latent RNA (LAT) is not required for latent infection in the mouse. Ho DY, Mocarski ES. Proc Natl Acad Sci U S A. 1989; 86 (19): 7596-600
• Beta-galactosidase as a marker in the peripheral and neural tissues of the herpes simplex virus-infected mouse. Ho DY, Mocarski ES. Virology. 1988; 167 (1): 279-83